Literature DB >> 25382234

Impact of locomotion training with a neurologic controlled hybrid assistive limb (HAL) exoskeleton on neuropathic pain and health related quality of life (HRQoL) in chronic SCI: a case study (.).

Oliver Cruciger1, Thomas A Schildhauer2, Renate C Meindl1, Martin Tegenthoff3, Peter Schwenkreis3, Mustafa Citak2, Mirko Aach1.   

Abstract

Chronic neuropathic pain (CNP) is a common condition associated with spinal cord injury (SCI) and has been reported to be severe, disabling and often treatment-resistant and therefore remains a clinical challenge for the attending physicians. The treatment usually includes pharmacological and/or nonpharmacological approaches. Body weight supported treadmill training (BWSTT) and locomotion training with driven gait orthosis (DGO) have evolved over the last decades and are now considered to be an established part in the rehabilitation of SCI patients. Conventional locomotion training goes along with improvements of the patients' walking abilities in particular speed and gait pattern. The neurologic controlled hybrid assistive limb (HAL®, Cyberdyne Inc., Ibraki, Japan) exoskeleton, however, is a new tailored approach to support motor functions synchronously to the patient's voluntary drive. This report presents two cases of severe chronic and therapy resistant neuropathic pain due to chronic SCI and demonstrates the beneficial effects of neurologic controlled exoskeletal intervention on pain severity and health-related quality of life (HRQoL). Both of these patients were engaged in a 12 weeks period of daily HAL®-supported locomotion training. In addition to improvements in motor functions and walking abilities, both show significant reduction in pain severity and improvements in all HRQoL domains. Although various causal factors likely contribute to abatement of CNP, the reported results occurred due to a new approach in the rehabilitation of chronic spinal cord injury patients. These findings suggest not only the feasibility of this new approach but in conclusion, demonstrate the effectiveness of neurologic controlled locomotion training in the long-term management of refractory neuropathic pain. Implications for Rehabilitation CNP remains a challenge in the rehabilitation of chronic SCI patients. Locomotion training with the HAL exoskeleton seems to improve CNP in chronic SCI. HAL locomotion training is feasible and safe in the rehabilitation of chronic SCI patients.

Entities:  

Keywords:  Chronic neuropathic pain; exoskeleton; health related quality of life; locomotion training; spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 25382234     DOI: 10.3109/17483107.2014.981875

Source DB:  PubMed          Journal:  Disabil Rehabil Assist Technol        ISSN: 1748-3107


  17 in total

1.  "Back at the same level as everyone else"-user perspectives on walking with an exoskeleton, a qualitative study.

Authors:  Gunn-Kristin Knudsen Thomassen; Vivien Jørgensen; Britt Normann
Journal:  Spinal Cord Ser Cases       Date:  2019-12-13

Review 2.  Robotic Rehabilitation and Spinal Cord Injury: a Narrative Review.

Authors:  Marwa Mekki; Andrew D Delgado; Adam Fry; David Putrino; Vincent Huang
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 3.  [Exoskeletons for rehabilitation of patients with spinal cord injuries. Options and limitations].

Authors:  M Aach; R C Meindl; J Geßmann; T A Schildhauer; M Citak; O Cruciger
Journal:  Unfallchirurg       Date:  2015-02       Impact factor: 1.000

4.  Long-term physical therapy for neuropathic pain after cervical spinal cord injury and resting state electroencephalography: a case report.

Authors:  Gosuke Sato; Michihiro Osumi; Ryo Mikami; Shu Morioka
Journal:  Spinal Cord Ser Cases       Date:  2022-04-09

5.  Hybrid assistive limb (HAL) treatment for patients with severe thoracic myelopathy due to ossification of the posterior longitudinal ligament (OPLL) in the postoperative acute/subacute phase: A clinical trial.

Authors:  Shigeki Kubota; Tetsuya Abe; Hideki Kadone; Yukiyo Shimizu; Toru Funayama; Hiroki Watanabe; Aiki Marushima; Masao Koda; Yasushi Hada; Yoshiyuki Sankai; Masashi Yamazaki
Journal:  J Spinal Cord Med       Date:  2018-10-18       Impact factor: 1.985

6.  The Effectiveness and Safety of Exoskeletons as Assistive and Rehabilitation Devices in the Treatment of Neurologic Gait Disorders in Patients with Spinal Cord Injury: A Systematic Review.

Authors:  Christian Fisahn; Mirko Aach; Oliver Jansen; Marc Moisi; Angeli Mayadev; Krystle T Pagarigan; Joseph R Dettori; Thomas A Schildhauer
Journal:  Global Spine J       Date:  2016-11-03

7.  Hybrid Assistive Limb Intervention in a Patient with Late Neurological Deterioration after Thoracic Myelopathy Surgery due to Ossification of the Ligamentum Flavum.

Authors:  Masakazu Taketomi; Yukiyo Shimizu; Hideki Kadone; Shigeki Kubota; Tetsuya Abe; Aiki Marushima; Tomoyuki Ueno; Ayumu Endo; Hiroaki Kawamoto; Akira Matsumura; Yoshiyuki Sankai; Yasushi Hada; Masashi Yamazaki
Journal:  Case Rep Orthop       Date:  2018-02-08

8.  Functional Outcome of Neurologic-Controlled HAL-Exoskeletal Neurorehabilitation in Chronic Spinal Cord Injury: A Pilot With One Year Treatment and Variable Treatment Frequency.

Authors:  Oliver Jansen; Thomas A Schildhauer; Renate C Meindl; Martin Tegenthoff; Peter Schwenkreis; Matthias Sczesny-Kaiser; Dennis Grasmücke; Christian Fisahn; Mirko Aach
Journal:  Global Spine J       Date:  2017-07-07

9.  Factors Predicting the Effects of Hybrid Assistive Limb Robot Suit during the Acute Phase of Central Nervous System Injury.

Authors:  Hideo Chihara; Yasushi Takagi; Kazunari Nishino; Kazumichi Yoshida; Yoshiki Arakawa; Takayuki Kikuchi; Yohei Takenobu; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-11-05       Impact factor: 1.742

10.  Reshaping of Gait Coordination by Robotic Intervention in Myelopathy Patients After Surgery.

Authors:  Sandra Puentes; Hideki Kadone; Shigeki Kubota; Tetsuya Abe; Yukiyo Shimizu; Aiki Marushima; Yoshiyuki Sankai; Masashi Yamazaki; Kenji Suzuki
Journal:  Front Neurosci       Date:  2018-03-02       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.